These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 21614414)
1. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Angiolillo DJ; Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Sumner S; Desai B; Charlton RK; Box LC; Zenni M; Guzman LA; Bass TA Thromb Haemost; 2011 Aug; 106(2):253-62. PubMed ID: 21614414 [TBL] [Abstract][Full Text] [Related]
2. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Angiolillo DJ; Capranzano P; Goto S; Aslam M; Desai B; Charlton RK; Suzuki Y; Box LC; Shoemaker SB; Zenni MM; Guzman LA; Bass TA Eur Heart J; 2008 Sep; 29(18):2202-11. PubMed ID: 18567918 [TBL] [Abstract][Full Text] [Related]
3. Impact of pentoxifylline on platelet function profiles in patients with type 2 diabetes mellitus and coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Ueno M; Ferreiro JL; Tomasello SD; Tello-Montoliu A; Capodanno D; Seecheran N; Kodali M; Dharmashankar K; Desai B; Charlton RK; Bass TA; Angiolillo DJ JACC Cardiovasc Interv; 2011 Aug; 4(8):905-12. PubMed ID: 21851906 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Desai B; Tello-Montoliu A; Rollini F; Angiolillo DJ Catheter Cardiovasc Interv; 2013 Jan; 81(1):42-9. PubMed ID: 22431415 [TBL] [Abstract][Full Text] [Related]
5. Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus. Suryadevara S; Ueno M; Tello-Montoliu A; Ferreiro JL; Desai B; Rollini F; Box LC; Zenni M; Guzman LA; Bass TA; Angiolillo DJ Thromb Haemost; 2012 Nov; 108(5):930-6. PubMed ID: 22782352 [TBL] [Abstract][Full Text] [Related]
6. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495 [TBL] [Abstract][Full Text] [Related]
7. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study. Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150 [TBL] [Abstract][Full Text] [Related]
8. Response to antiplatelet therapy is independent of endogenous thrombin generation potential. Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170 [TBL] [Abstract][Full Text] [Related]
9. Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease. Angiolillo DJ; Jakubowski JA; Ferreiro JL; Tello-Montoliu A; Rollini F; Franchi F; Ueno M; Darlington A; Desai B; Moser BA; Sugidachi A; Guzman LA; Bass TA J Am Coll Cardiol; 2014 Sep; 64(10):1005-14. PubMed ID: 25190236 [TBL] [Abstract][Full Text] [Related]
10. Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis. Nakagawa I; Wada T; Park HS; Nishimura F; Yamada S; Nakagawa H; Kichikawa K; Nakase H J Vasc Surg; 2014 Mar; 59(3):761-7. PubMed ID: 24239116 [TBL] [Abstract][Full Text] [Related]
11. Impact of adjunctive cilostazol therapy versus high maintenance dose of clopidogrel in suboptimal responders with diabetes mellitus. Ferreiro JL; Ueno M; Desai B; Capranzano P; Capodanno D; Angiolillo DJ Rev Esp Cardiol (Engl Ed); 2012 Jan; 65(1):105-6. PubMed ID: 21783310 [No Abstract] [Full Text] [Related]
12. Effect of cilostazol addition or clopidogrel doubling on platelet function profiles in diabetic patients undergoing a percutaneous coronary intervention. Ha SJ; Kim SJ; Hwang SJ; Woo JS; Kim W; Kim WS; Kim KS; Kim MK Coron Artery Dis; 2013 Dec; 24(8):690-7. PubMed ID: 24152567 [TBL] [Abstract][Full Text] [Related]
13. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent. Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250 [TBL] [Abstract][Full Text] [Related]
14. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. Angiolillo DJ; Bernardo E; Capodanno D; Vivas D; Sabaté M; Ferreiro JL; Ueno M; Jimenez-Quevedo P; Alfonso F; Bass TA; Macaya C; Fernandez-Ortiz A J Am Coll Cardiol; 2010 Mar; 55(11):1139-46. PubMed ID: 20223369 [TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. Jeong YH; Lee SW; Choi BR; Kim IS; Seo MK; Kwak CH; Hwang JY; Park SW J Am Coll Cardiol; 2009 Mar; 53(13):1101-9. PubMed ID: 19324253 [TBL] [Abstract][Full Text] [Related]
16. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Bal Dit Sollier C; Berge N; Boval B; Dubar M; Drouet L Thromb Haemost; 2010 Sep; 104(3):571-81. PubMed ID: 20664906 [TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The OPTIMUS (Optimizing Antiplatelet Therapy in Diabetes Mellitus)-4 Study. Franchi F; Rollini F; Aggarwal N; Hu J; Kureti M; Durairaj A; Duarte VE; Cho JR; Been L; Zenni MM; Bass TA; Angiolillo DJ Circulation; 2016 Sep; 134(11):780-92. PubMed ID: 27559041 [TBL] [Abstract][Full Text] [Related]
18. Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response. Good RI; McGarrity A; James TE; Miller H; McConnachie A; Goodall AH; Oldroyd KG Thromb Res; 2015 Jun; 135(6):1140-6. PubMed ID: 25746368 [TBL] [Abstract][Full Text] [Related]
19. Comparison of conventional aggregometry with VASP for monitoring P2Y12-specific platelet inhibition. Aradi D; Magyarlaki T; Tokés-Füzesi M; Rideg O; Vorobcsuk A; Komócsi A Platelets; 2010; 21(7):563-70. PubMed ID: 20642320 [TBL] [Abstract][Full Text] [Related]
20. Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study. Park Y; Jeong YH; Tantry US; Ahn JH; Kim KH; Koh JS; Park JR; Hwang SJ; Kwak CH; Hwang JY; Gurbel PA Thromb Haemost; 2014 Dec; 112(6):1198-208. PubMed ID: 25182660 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]